ANIFROLUMAB
anifrolumab 300 mg/2 mL injection, 2 mL vial
ANIFROLUMAB (14195D)
14195D
Manner of administration:Injection
Restriction
Indication: Systemic lupus erythematosus
Treatment phase: Initial treatment
Restriction
Indication: Systemic lupus erythematosus
Treatment phase: Continuing or recommencement of treatment (within 12 months of a treatment break)
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 5 | DPMQ: $1,448.00 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Saphnelo | |||||